Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Vitrolife AB (publ): Interim report January-March 2022: Building on our strong growth momentum

08:00 / 22 April 2022 Vitrolife Press release

First quarter
  • Sales of SEK 752 (379) million, corresponding to an increase of 98% in SEK whereof currency effect 13%, acquired growth 74% and organic growth 11%.
  • Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.
  • Strong growth in all market regions: Americas 255%, EMEA 85%, Japan Pacific 21% and Asia 19% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 228 (163) million, corresponding to a margin of 30.4% (43.0). EBITDA per share increased 13%.
  • Net income was SEK 82 (119) million, resulting in earnings per share of SEK 0.60 (1.09).
Pro forma
  • Sales, adjusted for discontinuing Covid business, increased by 18% in SEK, and 11% in local currencies.
  • EBITDA margin of 30.4% (34.4%).

Gothenburg, April 22, 2022
Thomas Axelsson, CEO


Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife is supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,200 people worldwide, headquartered in Gothenburg, Sweden.
Vitrolife's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aims to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.

Show as PDF

Show original from Cision


This information was distributed by Cision